Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

4-year Phase 1/2a open-label extension data for zorevunersen (added to standard anti-seizure therapy) reported substantial, durable reductions in seizures, alongside ongoing improvements in cognition and behavior. The results are framed as sustained efficacy and functional improvements over multiple years, supporting a constructive outlook for the program’s clinical trajectory.